EG BioMed is working closely with Taipei Medical University and its three affiliated hospitals to pioneer a revolutionary blood test for the early detection of ten major cancers. These cancers include some of the most common and deadly types, such as breast, colon, rectal, esophageal, stomach, lung, pancreatic, prostate, ovarian, uterine, and liver cancers. This cutting-edge technology promises to transform cancer screening and offer new hope to millions of patients.
In this game-changing collaboration, EG BioMed has commissioned Taipei Medical University to lead the clinical trials, with active recruitment of patients from Taipei Medical University Hospital, Shuang Ho Hospital, and Wan Fang Hospital. These trials will bring us one step closer to developing a precise and effective early cancer detection method.
EG BioMed’s expert team is responsible for conducting genome-wide DNA methylation assays, identifying novel biomarkers, and completing clinical validation. The company is also leading the commercialization and promotion of these groundbreaking technologies, ensuring that patients around the world can benefit from this revolutionary advancement.
The ultimate goal of this collaboration is to accelerate the innovation of cancer detection technologies, rewriting the future of early diagnosis and significantly improving patient outcomes. With the expansion of this technology, we believe more people will have the opportunity to receive accurate diagnoses and effective treatment in the early stages of cancer, saving countless lives.